SEC Form 4 · accession 0001140361-15-042182
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael G Grey
Director
Period of report
Nov 16, 2015
Accepted (ET)
Nov 18, 2015 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 16, 2015 | M | 7,500 | $38.59 | A | 33,750 | D | |
| Common StockF1,F2 | Nov 16, 2015 | S | 7,500 | $104.2738 | D | 26,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF1,F4,F3 | $38.59 | Nov 16, 2015 | M | 7,500 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on August 14, 2015.
- F2The price in column 4 is a weighted average price. The price actually received ranged from $102.98 to $106.81. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regarding the number of shares sold at each price within the range
- F3Original option grant vests 6/48ths on November 22, 2008, and 1/48th on the 22nd day of every month thereafter.
- F4Reflects the number of stocks options that remain outstanding from this specific stock option grant following the reported transaction.